



Updated: 04/2024  
DMMA Approved: 04/2024

**Request for Prior Authorization for Givlaari (givosiran)**

Website Form – [www.highmarkhealthoptions.com](http://www.highmarkhealthoptions.com)

Submit request via: Fax - 1-855-476-4158

All requests for Givlaari (givosiran) require a Prior Authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

**Givlaari (givosiran) Prior Authorization Criteria:**

For all requests for Givlaari (givosiran) all of the following criteria must be met:

Coverage may be provided with a diagnosis of acute hepatic porphyria (AHP) and the following criteria is met:

- Member must be 18 years of age or older
- Must be prescribed by or in consultation with a provider who specializes in porphyria (i.e. hematologist, hepatologist, gastroenterologist)
- Member must have active disease defined as having at least 2 documented porphyria attacks requiring hospitalization, urgent care visits, or IV hemin administration within the last 6 months.
- Documentation the members has had elevated urinary or plasma porphobilinogen (PBG) or aminolevulinic acid (ALA) levels with the past year (reference range must be provided)
- The requested dose and frequency is in accordance with FDA-approved labeling, nationally recognized compendia, and/or evidence-based practice guidelines
- **Initial Duration of Approval:** 6 months
- **Reauthorization criteria**
  - Documentation of a decrease in the number of porphyria attacks that require hospitalization, urgent healthcare visits, or IV hemin administration since starting the medication.
- **Reauthorization Duration of Approval:** 12 months

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peer-reviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case by case basis to determine medical necessity.

Drugs are authorized in generic form unless the branded product is on the preferred drug list or the prescriber has indicated in writing that the branded product is medically necessary. If only the branded product is on the preferred drug list, the generic form will be considered non-preferred and shall not require the prescriber to indicate in writing that the branded product is medically necessary.



Updated: 04/2024  
DMMA Approved: 04/2024

**GIVLAARI (GIVOSIRAN)  
PRIOR AUTHORIZATION FORM**

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation as applicable to Highmark Health Options Pharmacy Services. **FAX:** (855) 476-4158  
If needed, you may call to speak to a Pharmacy Services Representative.  
**PHONE:** (844) 325-6251 Monday through Friday 8:00am to 7:00pm

**PROVIDER INFORMATION**

Requesting Provider:	NPI:
Provider Specialty:	Office Contact:
Office Address:	Office Phone:
	Office Fax:

**MEMBER INFORMATION**

Member Name:	DOB:	
Member ID:	Member weight:	Height:

**REQUESTED DRUG INFORMATION**

Medication:	Strength:	
Directions:	Quantity:	Refills:
Is the member currently receiving requested medication? <input type="checkbox"/> Yes <input type="checkbox"/> No Date Medication Initiated:		
Is this medication being used for a chronic or long-term condition for which the medication may be necessary for the life of the patient? <input type="checkbox"/> Yes <input type="checkbox"/> No		

**Billing Information**

This medication will be billed:  at a pharmacy **OR**  
 medically (if medically please provide a JCODE: \_\_\_\_\_)

Place of Service:  Hospital  Provider's office  Member's home  Other

**Place of Service Information**

Name:	NPI:
Address:	Phone:

**MEDICAL HISTORY (Complete for ALL requests)**

Diagnosis:  Acute Hepatic Porphyria  Other: \_\_\_\_\_

Number of porphyria attacks within the last 6 months requiring hospitalization, urgent care visits, or IV hemin administration:  
Date of attacks : \_\_\_\_\_

plasma porphobilinogen (PBG) level (please provide date taken and reference range): \_\_\_\_\_

aminolevulinic acid (ALA) level (please provide date taken and reference range): \_\_\_\_\_

**CURRENT or PREVIOUS THERAPY**

Medication Name	Strength/ Frequency	Dates of Therapy	Status (Discontinued & Why/Current)

**REAUTHORIZATION**

Number of porphyria attacks within the last 6 months requiring hospitalization, urgent care visits, or IV hemin administration:  
Date of attacks : \_\_\_\_\_

**SUPPORTING INFORMATION or CLINICAL RATIONALE**




Updated: 04/2024  
DMMA Approved: 04/2024

Prescribing Provider Signature	Date